OraLiva, Inc.

Overview

OraLiva, Inc. is listed as a healthcare AI company in the New York City AI scene[1]. Founded in 2019, the company provides an AI-powered brush biopsy test that dentists can use chairside to detect oral cancer and dysplasia[2]. OraLiva's ONC In-Cyt platform processes brush biopsy samples through deep-learning algorithms trained on 13 million+ cell images to identify dysplasia and early malignancy[4]. The company claims over 95% accuracy in multi-center clinical trials and 10 years of research and development across AI, engineering and science[5]. OraLiva was co-founded by Dr. John T. McDevitt, Chief Scientific Officer, and Anna Grassini, President[10]. In October 2025, OraLiva closed a $2.0 million oversubscribed seed round[7], and in July 2025 received a Direct to Phase II SBIR grant from the National Institute of Dental and Craniofacial Research[8]. The device has not been reviewed by the FDA and is currently only for research use[11].

Growth & traction

OraLiva claims "Over 95% accuracy in multi-center clinical trials" and "10 years of R&D across AI, engineering and science". [5]

McDevitt (Co-Founder & Chief Scientific Officer), whose academic lab at NYU helped pioneer single-cell analysis, and Anna Grassini, JD (Co-Founder & President). [10]

Customers

On January 15, 2026 OraLiva announced a multi-state launch with Delta Dental of Michigan and Delta Dental of North Carolina covering non-invasive cytology and AI risk-stratification for dentists across Michigan, Ohio, Indiana and North Carolina. [6]

Funding history

On October 7, 2025 OraLiva announced the close of a $2.0 million oversubscribed seed round. [7]

On July 21, 2025 OraLiva announced it had been awarded a Direct to Phase II SBIR grant from the National Institute of Dental and Craniofacial Research. [8]

Partnerships

On March 9, 2026 OraLiva announced a partnership with Rovers Medical Devices to expand clinical applications of the Orcellex brush with its oral cancer screening test. [9]